Immunogenicity of COVID-19 Vaccinations in Autologous HSCT Recipients

This multicenter, prospective, non-interventional cohort study aims to evaluate data on humoral and cellular immune response generated within the COVID-19 vaccination standard in patients with B-cell non-Hodgkin lymphoma (NHL) or Hodgkin lymphoma (HL) who underwent autologous hematopoietic stem cell transplantation (HSCT).

Inclusion Criteria:Patient 42 days (±3) post autologous HSCT for B-cell non-Hodgkin lymphoma or Hodgkin lymphoma.Patient is 30 years of age or older at enrollment.Patients are eligible for study inclusion with or without confirmed SARS-CoV-2 infection prior to autologous HSCT.Patient is treated at an institution that practices the standard-of-care COVID-19 vaccination.Patient has received 3 or more vaccinations with an anti-SARS-CoV-2 mRNA vaccine prior to autologous HSCT.Patient planned to be vaccinated against COVID-19 according to the hospital standard.Written informed consent from patient has been obtained prior to any study related procedures.Exclusion Criteria:Patient with confirmed SARS-CoV-2 infection between d0 and d42 after autologous HSCT.Patient has a positive SARS-CoV-2 antigen test at visit d42.Patient has received less than 3 vaccinations with an anti-SARS-CoV-2 mRNA vaccine prior to autologous HSCT.Use of any investigational or non-registered product (vaccine or drug) within 28 days preceding enrollment.Planned use during the study of any investigational or non-registered product (vaccine or drug).